(AVD) American - Overview
Stock: Insecticides, Fungicides, Herbicides, Soil Fumigants, Biorationals
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.3% |
| Relative Tail Risk | -9.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.05 |
| Alpha | -29.84 |
| Character TTM | |
|---|---|
| Beta | 0.832 |
| Beta Downside | 0.942 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.70% |
| CAGR/Max DD | -0.45 |
Description: AVD American January 18, 2026
American Vanguard Corporation (NYSE:AVD) develops, manufactures, and markets a broad portfolio of chemical, biological, and biorational products for agricultural, commercial, and consumer applications worldwide. Its product line includes insecticides, fungicides, herbicides, soil-health amendments, plant nutrition solutions, molluscicides, growth regulators, soil fumigants, and other biorationals delivered in liquid, powder, or granular forms for crops, turf, ornamental plants, and human/animal health protection. Distribution is handled through national distributors, buying groups, co-operatives, and a network of sales offices, agents, and wholly-owned distributors.
Key recent metrics (as of FY 2024 Q3) show AVD generating approximately $210 million in revenue, with a gross margin of 31% and an operating cash flow conversion of 0.9×, reflecting modest profitability in a price-sensitive agro-chemical market. The company’s growth is closely tied to three sector drivers: (1) rising global fertilizer demand driven by a projected 3.5% CAGR in crop production; (2) increasing adoption of biorational and low-toxicity solutions amid stricter environmental regulations; and (3) volatile commodity prices that affect farmer input spending, which historically correlates with a 0.6 elasticity for agro-chemical sales.
For a deeper dive into AVD’s valuation, competitive positioning, and scenario analysis, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -112.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -6.76 > 1.0 |
| NWC/Revenue: 33.26% < 20% (prev 36.08%; Δ -2.82% < -1%) |
| CFO/TA 0.01 > 3% & CFO 6.63m > Net Income -112.1m |
| Net Debt (183.8m) to EBITDA (5.90m): 31.17 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.5m) vs 12m ago 1.20% < -2% |
| Gross Margin: 24.11% > 18% (prev 0.27%; Δ 2383 % > 0.5%) |
| Asset Turnover: 74.95% > 50% (prev 72.93%; Δ 2.02% > 0%) |
| Interest Coverage Ratio: -0.48 > 6 (EBITDA TTM 5.90m / Interest Expense TTM 17.1m) |
Altman Z'' 3.02
| A: 0.27 (Total Current Assets 406.5m - Total Current Liabilities 230.2m) / Total Assets 655.0m |
| B: 0.28 (Retained Earnings 183.2m / Total Assets 655.0m) |
| C: -0.01 (EBIT TTM -8.13m / Avg Total Assets 707.2m) |
| D: 0.40 (Book Value of Equity 175.3m / Total Liabilities 434.0m) |
| Altman-Z'' Score: 3.02 = A |
Beneish M -3.06
| DSRI: 1.18 (Receivables 180.6m/159.7m, Revenue 530.1m/553.8m) |
| GMI: 1.14 (GM 24.11% / 27.46%) |
| AQI: 0.85 (AQ_t 0.27 / AQ_t-1 0.32) |
| SGI: 0.96 (Revenue 530.1m / 553.8m) |
| TATA: -0.18 (NI -112.1m - CFO 6.63m) / TA 655.0m) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of AVD shares?
Over the past week, the price has changed by -1.77%, over one month by +27.62%, over three months by +0.81% and over the past year by -9.27%.
Is AVD a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AVD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12 | 140.5% |
| Analysts Target Price | 12 | 140.5% |
| ValueRay Target Price | 3.8 | -24.6% |
AVD Fundamental Data Overview February 03, 2026
P/S = 0.2728
P/B = 0.6467
P/EG = 2.27
Revenue TTM = 530.1m USD
EBIT TTM = -8.13m USD
EBITDA TTM = 5.90m USD
Long Term Debt = 182.2m USD (from longTermDebt, last quarter)
Short Term Debt = 6.18m USD (from shortTermDebt, last quarter)
Debt = 200.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 183.8m USD (from netDebt column, last quarter)
Enterprise Value = 328.4m USD (144.6m + Debt 200.6m - CCE 16.8m)
Interest Coverage Ratio = -0.48 (Ebit TTM -8.13m / Interest Expense TTM 17.1m)
EV/FCF = 112.7x (Enterprise Value 328.4m / FCF TTM 2.91m)
FCF Yield = 0.89% (FCF TTM 2.91m / Enterprise Value 328.4m)
FCF Margin = 0.55% (FCF TTM 2.91m / Revenue TTM 530.1m)
Net Margin = -21.15% (Net Income TTM -112.1m / Revenue TTM 530.1m)
Gross Margin = 24.11% ((Revenue TTM 530.1m - Cost of Revenue TTM 402.3m) / Revenue TTM)
Gross Margin QoQ = 28.68% (prev 31.36%)
Tobins Q-Ratio = 0.50 (Enterprise Value 328.4m / Total Assets 655.0m)
Interest Expense / Debt = 2.16% (Interest Expense 4.32m / Debt 200.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -6.42m (EBIT -8.13m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.77 (Total Current Assets 406.5m / Total Current Liabilities 230.2m)
Debt / Equity = 0.91 (Debt 200.6m / totalStockholderEquity, last quarter 221.0m)
Debt / EBITDA = 31.17 (Net Debt 183.8m / EBITDA 5.90m)
Debt / FCF = 63.07 (Net Debt 183.8m / FCF TTM 2.91m)
Total Stockholder Equity = 228.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.85% (Net Income -112.1m / Total Assets 655.0m)
RoE = -49.15% (Net Income TTM -112.1m / Total Stockholder Equity 228.1m)
RoCE = -1.98% (EBIT -8.13m / Capital Employed (Equity 228.1m + L.T.Debt 182.2m))
RoIC = -1.61% (negative operating profit) (NOPAT -6.42m / Invested Capital 399.7m)
WACC = 4.75% (E(144.6m)/V(345.2m) * Re(8.98%) + D(200.6m)/V(345.2m) * Rd(2.16%) * (1-Tc(0.21)))
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.44%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈23.6m ; Y1≈15.5m ; Y5≈7.08m
Fair Price DCF = 1.47 (EV 225.5m - Net Debt 183.8m = Equity 41.7m / Shares 28.5m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -55.11 | EPS CAGR: -7.51% | SUE: -0.95 | # QB: 0
Revenue Correlation: -55.05 | Revenue CAGR: -7.47% | SUE: -1.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.06 | Chg30d=+0.010 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.38 | Chg30d=+0.010 | Revisions Net=-1 | Growth EPS=+392.3% | Growth Revenue=+3.5%